BDC readies $135M in biotech venture cash; GSK inks $196M deal on anthrax treatment;

@FierceBiotech: Popular yesterday from FierceBiomarkers: 12-year study flags new biomarker for high risk of diabetes. Article | Follow @FierceBiotech

@JohnCFierce: Google is making waves in biotech, glad Google Ventures' Krishna Yeshwant is speaking at our Oct. 15 event in Boston. Register here | Follow @JohnCFierce

@EmilyMFierce: ICYMI yesterday: Stem cell therapy protects vision in preclinical retinal disease study. More from FierceBiotech Research | Follow @EmilyMFierce

> The Business Development Bank of Canada has reserved $135 million in venture cash for biotechs, devices and new tech companies in the healthcare arena. Report

> Under a new contract GlaxoSmithKline ($GSK) has agreed to supply the U.S. government $196 million worth of their anthrax treatment raxibacumab. Story

> Durata Therapeutic has moved into newly renovated offices. Story

> Sangamo Biosciences has priced an offering at $10.58 a share. Release

Medical Device News

@FierceMedDev: Doctors may be overusing MRI facilities they own. More from FierceDiagnostics | Follow @FierceMedDev

@DamianFierce: Covidien plots job cuts, plant closures to save $300M. News | Follow @DamianFierce

@MarkHFierce: Agilent will split in two, keeping its growing Dx business under the current name. Press release | Follow @MarkHFierce

@MichaelGFierce: The artificial pancreas combines an insulin pump with a continuous glucose monitor. Who will get one to market first? Feature from FierceDrugDelivery | Follow @MichaelGFierce

> Roche links with Boehringer Ingelheim in companion Dx deal. Story

> GE-commissioned survey blasts neurological disease Dx delays. Item

> Edwards hit with shareholder suit over 'misleading' Sapien claims. Article

> Nanosphere snags $30.2M in stock sale. Report

Pharma News

@FiercePharma: Still trending on our website: FDA turbocharges Glaxo's bids for new cancer drug uses. Article | Follow @FiercePharma

@CarlyHFierce: Gold-encrusted mooncakes stuffed with shark's fin "out of favor" in China; corruption crackdown has killed demand. More from Reuters | Follow @CarlyHFierce

> Roche chief tamps down talk of $13.5B BioMarin buyout. Story

> Sanofi CEO: Thanks to Genzyme, investors take us seriously. Report

Vaccines News

> Study links delayed vaccines to increased risk of whooping cough. More

> Unvaccinated clusters bear brunt of bad year for measles in U.S. Story

> Brain cancer vaccine data gives Agenus' stock a boost. Article

> India gives 114 kids the wrong vaccine in polio mix-up. News

> NIH trialing Sanofi H7N9 vaccine with GSK, Novartis adjuvants. Report

> Visterra advances universal flu antibody to cusp of Phase I. Item

Pharma Manufacturing News

@EricPFierce: Bad luck for this Shamrock. FDA clobbers it with a consent decree and permanent injunction. More | Follow @EricPFierce

> Hikma, partner to build $20M plant in Ethiopia. Story

> FDA uncovers big foul-ups at Ranbaxy plant. Article

> Aesica invests $48M in U.K. plant to make diabetes drugs. News

> MIT works on process to manufacture biologics in 24 hours. Item

And Finally... A parasite found in cat feces has been found to have brain-altering properties. More

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.